Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
about
Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer DrugsLong-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology groupPhysiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryAn improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIα and potent anticancer agent.The Current and Future Therapies for Human Osteosarcoma.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialDecreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.Olaratumab for the treatment of soft-tissue sarcoma.Anthraquinones As Pharmacological Tools and Drugs.Cardiovascular disease in cancer survivors.Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice.Prevention and treatment of doxorubicin-induced cardiotoxicity by dexrazoxane and schisandrin B in rabbits.Dexrazoxane mitigates epirubicin-induced genotoxicity in mice bone marrow cells.Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity.Topoisomerases as anticancer targets.
P2860
Q28070311-C0F6C20D-FBBA-40ED-91BC-93A6827FF007Q34992080-12393C53-E8AF-489B-8F71-42E867BB5198Q35039202-8858E986-A3AD-41E4-BB9C-9D2CA64FB0EEQ35269036-01762B86-0CE6-47F7-A261-5D8C576DD6ADQ36514299-DF027D7F-D14A-4EAF-A483-DC6EB4D49AAEQ36551901-76472343-C542-4854-9693-10D799C479A4Q37129069-A6517DE8-B77A-4E76-BC9D-9C0268334797Q37613120-E8AA63D3-D296-4EDD-80B5-58B41F9B249CQ38190105-4293435E-9F31-49DE-A580-1159DAC753D4Q38651664-8FC96993-10E8-4832-97BF-EA1986CD058EQ38816745-FB9E4F9F-2773-4E47-9730-C27BF8EB5810Q39103481-FA559A4F-CC30-41FA-AA33-5C29C0A8F5B8Q40234181-CCC93D40-5871-45A5-92F9-2FCA30F43A82Q42726091-698C5A4F-0FAE-4D91-9FD4-861314BED554Q46612630-100F7DDF-00A4-45B5-82A2-33020F51DBE3Q46717036-4F10D086-F0E9-4BCA-807F-2DC4F2873107Q47106589-DA176B20-EDEB-4DF7-8A2D-E4FCF15D76E8Q47594138-AE8A417B-E36C-44B1-AE33-6A23FE3E70BEQ49832269-39DBD3C1-7AE1-4B1B-A057-6E7E94F1E692
P2860
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@ast
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@en
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@nl
type
label
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@ast
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@en
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@nl
prefLabel
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@ast
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@en
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@nl
P2860
P3181
P1476
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity
@en
P2093
Robin L Jones
P2860
P304
P3181
P356
10.1586/14779072.6.10.1311
P407
P577
2008-11-01T00:00:00Z